Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.